Yum China Shares Rise on Fourth-Quarter Earnings Beat
By Amanda Lee
Yum China shares rose in early trading in Hong Kong after the restaurateur's quarterly results beat expectations, helped by new store openings and higher consumption activity, and said it would step up plans for buybacks in 2024.
Shares were up 14.5% to HK$332.00 at midday Wednesday, bringing shares into the green for the year.
Yum China said before markets opened that its fourth quarter net profit rose 81% on year to US$97 million, beating a median analyst estimate of US$61.9 million in a FactSet poll. The bottom line was helped by sales that rose 19% on year to US$2.49 billion--beating in a FactSet poll of US$2.32 billion.
The company opened 542 net new stores in the quarter. It also highlighted plans to step up buybacks, boost its cash dividend, and open up to 1,700 new stores in China this year.
Jefferies analysts Anne Ling and Lisa Liao said in a research note that the bottom line came in far higher than they expected, helped by a lower-than-expected tax rate and investment loss. A 23% rise in dividend was "a nice positive surprise," they added. Jefferies kept a buy rating with a target price of HK$510.70.
Citi analysts Xiaopo Wei and Brian Cho said in a note that the results dispelled market concerns on margin pressure from competition. Citi has a buy rating with a target price of HK$573.56 on the stock.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
February 06, 2024 23:57 ET (04:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth